Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bumetanide for the Autism Spectrum Clinical Effectiveness Trial
2016-002875-81Phase 2Active
- Sponsor
- University Medical Center Utrecht
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of bumetanide in Autism Spectrum Disorder (ASD), attention deficit hyperactivity disorder (ADHD), epilepsy and 1 more, sponsored by University Medical Center Utrecht. Primary endpoint: Aberrant Behavior Checklist (ABC) irritability subscale. Started Oct 2016; status: active.
02
Drugs
bumetanide
03
Conditions
Autism Spectrum Disorder (ASD)attention deficit hyperactivity disorder (ADHD)epilepsymental disorder
Beyond the preview
Go deeper on 2016-002875-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002875-81.